Moreover, Trametinib has recently been approved for the treatment of adult BRAF-mutated melanoma, while different clinical trials with Selumetinib and MEK162 show promising results in adult patients with RAS/RAF mutation positive melanoma and non-small-cell lung cancer [14–18]. This evidence concerns the gene BRAF and melanoma.